Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc)

Ritesh Gupta a, Anoop Misra a, b, c, *

a Fortis CDOC Hospital, Chirag Enclave, New Delhi, India
b National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India
c Diabetes Foundation (India), New Delhi, India

Abstract

Background and aims: Multiple issues in management of COVID have emerged, but confusion persists regarding rational interpretation. Aim of this brief review is to review these issues based on current literature.

Methods: This is a narrative review with Pubmed and Google Scholar search till 23 March 2020. Search terms were, COVID-19, treatment of coronavirus, COVID 19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and gastrointestinal disease.

Results: We discuss evidence regarding role of chloroquine and hydroxychloroquine in treatment and prophylaxis, use of inhibitors of the renin angiotensin system, safety of ibuprofen, unusual clinical features like gastrointestinal symptoms and interpretation of tests for cardiac enzymes and biomarkers.

Conclusions: While our conclusions on management of COVID-19 patients with co-morbidities are based on current evidence, however, data is limited and there is immediate need for fast track research.

1. Introduction

We recently published an article highlighting the special concerns while managing patients with diabetes in the times of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona Virus Disease 2019) COVID-19 pandemic [1]. More data has accumulated since then about this ever-evolving pandemic and several new concerns and concepts have emerged. We considered it worthwhile to highlight some of these issues and try to arrive at some rational conclusion based on the current evidence. Detailed articles on each of below mentioned issues will be published shortly.

2. Search methodology

We systematically searched the PubMed database and Google Scholar till March 23, 2020 using the keywords COVID-19, treatment of coronavirus, COVID 19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and gastrointestinal disease. We also accessed the and retrieved the full text of the relevant cross references from the search results.

3. Role of chloroquine and hydroxychloroquine (HCQ)

Antiviral properties of chloroquine in vitro have been observed for more than a half a century [2]. It exerts its antiviral effect by several mechanisms: reducing endocytosis of virus by stabilising the lysosomes, inhibiting the viral replication, and inducing the production of non-infectious particles by inhibition of glycosylation of the envelope glycoproteins [3]. Additionally, it exerts anti-inflammatory effects by inhibiting the release of proinflammatory
cytokines, especially tumor necrosis factor-alpha which may ameliorate the immune reaction seen with viral infections.

*In vitro* activity of chloroquine (CQ) has been demonstrated against several viruses including Vesicular Stomatitis virus [4], Mouse Hepatitis virus, Nipah virus, Ebola virus, Influenza virus, and more recently, SARS coronavirus [5,6]. However, except for human immunodeficiency virus and hepatitis C virus, these effects have not been replicated in clinical studies in humans. CQ did not prevent influenza infection in a randomized, double-blind, placebo-controlled clinical trial [7]. Further, there was no effect on patients with dengue infection in a randomized controlled trial [8]. Of concern was the observation that despite having antiviral activity *in vitro*, CQ increased viral replication and exacerbated fever in animal models of chikungunya virus infection [9]. Also, patients with chikungunya virus infection had more chronic arthralgia when treated with CQ vs. those treated with placebo [10]. The reasons for this discrepancy between *in vitro* and results from clinical studies are not very clear. One possible mechanism would be the failure of the drug to concentrate in target tissues. Also 50% effective concentration [EC50] of chloroquine for anti-viral effects is about three times higher than that necessary to inhibit chloroquine-sensitive malarial parasites [11].

Against this background, CQ was evaluated in SARS CoV-2 infection and showed very good in vitro efficacy [12]. The clinical evidence was recently published from France. In this study of 36 patients, 20 patients were treated with hydroxychloroquine (HCQ), out of which 6 also received azithromycin, and 16 patients served as controls. At day 6 post treatment the proportion of patients who were negative for SARS CoV-2 was 100%, 57% and 12.3% for those treated with CQ and azithromycin combination, HCQ only and controls, respectively [13]. Though this is a small study, the results are very encouraging. Further, a report from China showed good efficacy of CQ in patients with COVID-19, though there was no access to detailed data [14]. Concurrently, several trials are planned to study its role in prevention and treatment of COVID-19 and at present, it is difficult to make recommendations based on these preliminary data.

3.1. Practical recommendations based on current evidence

In view of good tolerability of HCQ and low cost, it could be offered as an off-label treatment to the patients with moderate to severe COVID-19 infection. These issues have been discussed in detail in another article in this special issue [15].

Though there is no evidence of the role of chloroquine in prophylaxis against COVID-19, Indian Council of Medical Research (ICMR) has recommended prophylaxis with CQ or HCQ in asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19 and asymptomatic household contacts of laboratory confirmed cases [16].

4. Use of ibuprofen and other NSAIDs

A doctor from France cited four cases of young patients with COVID-19 and no underlying health problems who went on to develop serious symptoms after using non-steroidal anti-inflammatory drugs (NSAIDs) in the early stage of disease. This observation prompted the advice against the use of ibuprofen in this condition [17]. World Health Organisation (WHO) first recommended against using ibuprofen in COVID-19, however went back against its own advice and updated its advice soon to say that “based on currently available information, WHO does not recommend against the use of ibuprofen” [18]. It is interesting to note that several previous studies have shown a complicated course with increased incidence of empyema, lung cavitation and prolonged stay in the intensive care unit when nonsteroidal anti-inflammatory drugs (NSAIDs) were used in patients with pneumonia [19].

4.1. Practical recommendation based on current evidence

Overall, it seems reasonable, but not mandatory, to avoid ibuprofen and other NSAIDs in COVID-19 infection and use acetaminophen instead for control of fever and pain.

5. Use of drugs acting on renin angiotensin system

Angiotensin converting enzyme-2 (ACE-2) is the receptor for SARS CoV-2 as well as other coronaviruses and is expressed in type 2 alveolar epithelial cells and endothelium. The S-glycoprotein on the surface of coronavirus binds to ACE2. This leads to a conformational change in the S-glycoprotein and allows proteolytic digestion by host cell proteases (TMPRSS2) ultimately leading to internalization of the virion [20]. Viral S-glycoprotein, TMPRSS2 and ACE-2 inhibition are potential targets of therapy and possibly vaccine development.

As ACE-2 is the binding site for SARS CoV-2, its blockade is thought to be beneficial in preventing/treating this infection. A retrospective analysis showed reduced rates of death and endotracheal intubation in patients with viral pneumonia who were continued on ACE inhibitors [21]. Mice with coronavirus induced lung injury showed improvement when treated with an angiotensin receptor blocker, losartan [22]. As far as COVID-19 infection is concerned, the data on RAS activation or the effect of its blockade is limited at present. Hypokalaemia and hypertension? could be a marker of RAS activation and high incidence of hypokalaemia has been reported in patients with COVID-19 infection [23].

Despite these small studies suggesting the benefit of drugs acting on RAS pathway, there is some data, albeit scarce, from animal models and human studies that treatment with ACE inhibitors and ARB could cause up regulation of ACE2 [24]. Ibuprofen and thiazolidinediones have also been shown to do the same [25,26]. Increased expression of ACE2 could theoretically increase the risk of infection with SARS CoV-2. This could be a concern in people with diabetes who are at already elevated risk of infections because of many other factors. However, there is no evidence to support this hypothesis currently. In a retrospective analysis of 112 COVID-19 hospitalised patients with cardiovascular disease in Wuhan, there was no significant difference in the proportion of ACEI/ARB medication between non-survivors and survivors [27]. This issue will be discussed in detail in another article to be published in special issue shortly.

5.1. Practical recommendation based on current evidence

In view of lack of robust evidence for either benefit or harm, it is reasonable for patients to continue using ACE inhibitors and ARB, as recommended by European Society of Cardiology Council on Hypertension, European Society of Hypertension and American Heart Association [28–30].

6. Extrapulmonary manifestations

ACE-2 receptor, the binding site for SARS CoV-2 is expressed in several extrapulmonary locations, the chief amongst them being the gastrointestinal epithelium, renal tubules and Leydig cells in testis [31]. This raises concerns about some of the extrapulmonary manifestations and possible complications.
6.1. Gastrointestinal tract and liver

A significant number of patients with COVID-19 have reported diarrhea, vomiting and abdominal pain [32]. This is not unexpected as ACE-2 is highly expressed in the small intestinal epithelium [33]. These observations underscore the importance of considering COVID-19 while evaluating a patient with fever, cough and diarrhea.

ACE-2 receptor expression has also been seen in bile duct epithelial cells. Liver function test abnormalities have been observed in patients with COVID-19 [34]. Steatosis and liver injury have been reported [35]. These could be because of the direct effects of virus or adverse effects of drugs.

6.2. Kidneys

Patients with chronic kidney disease and those who have received renal transplant are at increased risk of COVID-19 infection and severity. Moreover, there are frequent renal function abnormalities and increased incidence of acute kidney injury in patients with COVID-19. It is not known yet whether this occurs from the effects of sepsis or is a direct nephrotoxic action of virus. Patients with acute kidney injury have a higher mortality and renal function monitoring should be a part of managing these patients.

6.3. Cardiovascular system

Patients with underlying cardiovascular disease are among the highest risk individuals for severe COVID-19 disease and death [36]. Cardiac troponin levels are significantly increased in patients with severe SARS-CoV-2 infection compared to those with milder forms of disease [37]. This may be similar to what is observed in many patients with acute respiratory illnesses; or it may indicate myocardial injury because of the virus as ACE-2 receptors are widely expressed on cardiomyocytes. American College of Cardiology recommends measuring troponin if the diagnosis of acute MI is being considered on clinical grounds and an abnormal troponin should not be considered evidence for an acute MI without corroborating evidence [38]. Similarly, patients with COVID-19 infection have elevated natriuretic peptides, significance of which is uncertain. Hence an elevated level of natriuretic peptides in patients with acute respiratory illnesses; or it may indicate reproductive function may need to be followed up in men who have recovered from this infection.

6.4. Tests

Orchitis was reported in infection with SARS CoV earlier [39]. ACE-2 receptors are present in Leydig cells in testis. At present, there is no data about clinical significance of these receptors; however, reproductive function may need to be followed up in men who have recovered from this infection.

7. Conclusion

There are several unresolved clinical issues and dilemmas in the clinical management of COVID-19. This is not an expected considering the rapidity with which this disease has emerged and is progressing. We have attempted to go through the data available at present and arrive at some reasonable conclusion. However, these recommendations are not final as the evidence is accumulating daily and our understanding of the virus, the disease, its clinical presentation and management is rapidly evolving.

References

[1] Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr 2020 Mar 10;14(3):211–2.

[2] Shimizu Y, Yamamoto S, Homma M, Ishida N. Effect of chloroquine on the growth of animal viruses. Arch Gesamt Virusforsch 1972;36(1):93–104.

[3] Savarino A, Boelhaar JT, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003 Nov;3(11):722–7.

[4] Miller DK, Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci U S A 1981;78(24):8305–9.

[5] Keyaerts E, Li S, Vijgen L, Ryman E, Verbeek J, Van Ranst M, Maes P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009;53(8):3416–21. https://doi.org/10.1128/AAC.01509-08.

[6] Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol 1969 Mar;4(2):203–14.

[7] Paton NI, Lee I, Xu Y, Ooi EE, Cheung YB, Archuleta S, Wong G, Wilder-Smith A. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011;11(9):677–83. https://doi.org/10.1016/S1473-3099(11)70065-2.

[8] Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP. A randomised controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010 Aug 10;4(8):e785. https://doi.org/10.1371/journal.pntd.0000785.

[9] Roques P, Thiberville SD, Dupuis-Maguirara L, Lum FM, Labadie K, Martinon F, Gras L, Geog F, Ng LFP, de Lamballerie X. Le Grand R. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 2018;10(5):E268. https://doi.org/10.3390/v10050268.

[10] De Lamballerie X, Boissier V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008;8(6):837–9. https://doi.org/10.1089/vbz.2008.0049.

[11] Savarino A. Use of chloroquine in viral diseases. Lancet Infect Dis 2011;11(9):653–4. https://doi.org/10.1016/S1473-3099(11)70092-5.

[12] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269–71. https://doi.org/10.1038/s41422-020-0282-0. 10-0282.

[13] Gautret P, Haddad E, Lagier J-C, Parola P,肖 BO, De Lamballerie X, Boissier V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R, On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008;8(6):837–9. https://doi.org/10.1089/vbz.2008.0049.

[14] De Lamballerie X, Boissier V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008;8(6):837–9. https://doi.org/10.1089/vbz.2008.0049.

[15] Savarino A, Singh A, Shaikh A, Singh R, Misra A. Chloroquine or Hydroxychloroquine in the treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949.

[16] Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020 Mar 16;14(1):72–3. https://doi.org/10.5582/bt.2020.01.0047.

[17] Day M. Covid-19:Ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020 Mar 17;368:m1086. https://doi.org/10.1136/bmj.m1086.

[18] Updated: WHO now doesn’t recommend avoiding ibuprofen for COVID-19 symptoms. https://www.sciencealert.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms.

[19] Vosrot G, Philippot Q, Elbim C, Chalumeau, Fartoukh M. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med 2019;8(6):E786. https://doi.org/10.3390/jcm8060786.

[20] Gautret P, Haddad E, Lagier J-C, Parola P,肖 BO, De Lamballerie X, Boissier V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008;8(6):837–9. https://doi.org/10.1089/vbz.2008.0049.

[21] Henry C, Zaitzefon M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. SAVE Proc 2018;31(4):419–23.

[22] Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, Yang X, Zhang L, Duan Y, Zhang S, Chen W, Zhen W, Gai M, Penninger JM, Jiang C, Wang X. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014;4:7027.

[23] Chen D, Li X, Song G, Hu C, Su F, Dai J, Ye Y, Huangzl, Zhang X. Hypokalemia and clinical implications in patients with Coronavirus Disease 2019 (COVID-19). medRxiv preprint doi: https://doi.org/10.1101/2020.02.27.20028530.

[24] Li XC, Zhang J, Zhao J. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res 2017;125:21–30.

[25] Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, Guo H, Yan C, Sun H, Hu G, Yin X. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiovasc 2015;131(2):97–105.

[26] Zheng W, Xu YZ, Liu B, Wu R, Yang YY, Xiao QX, Zhang X. Pioglitazone
upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. Sci. World J. 2014;2014:603409. https://doi.org/10.1155/2014/603409.

[27] Peng YD, Meng K, Guan HQ, Leng L, Zhu RM, Wang BY, He MA, Cheng LX, Huang K, Zeng QT. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xinxueguanbing Za Zhi 2020 Mar 2;48:E004. https://doi.org/10.3760/cma.j.cn112148-20200220-00105.

[28] Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang; Mar 11 2020.

[29] ESH statement on COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/; March 12, 2020.

[30] HFSA/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.

[31] Fan C, Li K, Ding Y, Lu W, Wang J. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. medRxiv preprint doi: https://doi.org/10.1101/2020.02.12.20022418.

[32] Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, Gao XZ, Qi W, Wang MY. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 2020 Mar 5. https://doi.org/10.1136/gutjnl-2020-320891. pii: gutjnl-2020-320891.

[33] Liang W, Feng Z, Rao S, Xiao C, Yue X, Lin Z, Zhang Q, Qi W. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020 Feb 26. https://doi.org/10.1136/gutjnl-2020-320832. pii: gutjnl-2020-320832.

[34] Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, Zhang T, Chen XM, Lu FM. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi 2020 Feb 20;28(2):E002. https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.002.

[35] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020. https://doi.org/10.1016/S2213-2600(20)30076-X.

[36] Wang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020 Mar 12. https://doi.org/10.1016/j.ijid.2020.03.017. pii: S1201-9712(20)30136-3.

[37] Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis 2020 Mar 10. https://doi.org/10.1016/j.pcad.2020.03.001. pii: S0033-0620(20)30053-4.

[38] American College of Cardiology. Troponin and BNP use in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19.

[39] Xu J, Qi L, Chi X, Yang J, Wei X, Geng E, Peh S, Gu J. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol Reprod 2006 Feb;74(2): 410–6.